These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26588198)

  • 1. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
    J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q; Schroeder JA; Kuether EL; Montgomery RR
    J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
    Girard TJ; Lasky NM; Grunz K; Broze GJ
    J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
    Stagaard R; Ley CD; Almholt K; Olsen LH; Knudsen T; Flick MJ
    Blood Adv; 2018 Nov; 2(22):3126-3136. PubMed ID: 30459211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.
    Werwitzke S; Vollack N; von Hornung M; Kalippke K; Kutzschbach J; Trummer A; Ganser A; Tiede A
    Thromb Haemost; 2015 Nov; 114(6):1127-35. PubMed ID: 26245154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.
    Lai JD; Cartier D; Hartholt RB; Swystun LL; van Velzen AS; den Haan JMM; Hough C; Voorberg J; Lillicrap D
    J Thromb Haemost; 2018 Mar; 16(3):533-545. PubMed ID: 29285874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
    Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
    J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
    J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
    Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A possible mechanism for Inv22-related F8 large deletions in severe hemophilia A patients with high responding factor VIII inhibitors.
    Fujita J; Miyawaki Y; Suzuki A; Maki A; Okuyama E; Murata M; Takagi A; Murate T; Suzuki N; Matsushita T; Saito H; Kojima T
    J Thromb Haemost; 2012 Oct; 10(10):2099-107. PubMed ID: 22906111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation.
    Radic CP; Rossetti LC; Abelleyro MM; Tetzlaff T; Candela M; Neme D; Sciuccati G; Bonduel M; Medina-Acosta E; Larripa IB; de Tezanos Pinto M; De Brasi CD
    J Thromb Haemost; 2015 Apr; 13(4):530-9. PubMed ID: 25611311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.
    Kosloski MP; Shetty KA; Wakabayashi H; Fay PJ; Balu-Iyer SV
    AAPS J; 2014 Sep; 16(5):1038-45. PubMed ID: 24934295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.